Literature DB >> 19110909

Sociodemographic factors predict early discontinuation of HIV non-nucleoside reverse transcriptase inhibitors and protease inhibitors.

Shaheena Asad1, Todd Hulgan, Stephen P Raffanti, Jim Daugherty, Wayne Ray, Timothy R Sterling.   

Abstract

BACKGROUND/
OBJECTIVE: HIV infection has a devastating impact on individual and public health, and affects populations disproportionately. Treatment with antiretroviral therapy (ART) saves lives, but long-term adherence to ART is critical to its success. We performed an observational cohort study to determine the influence of race, sex and other sociodemographic factors on early ART discontinuations among HIV-infected persons.
METHODS: TennCare-enrolled adults of black or white non-Hispanic race beginning ART with either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI) between 1996-2003 (N=3654) were assessed for early discontinuation. A subgroup of discontinuations was validated using the primary medical record.
RESULTS: Blacks were more likely than whites to discontinue NNRTIs (37 vs. 28%; P=0.003) and PIs (36 vs. 25%; P < or = 0.001). In multivariable models adjusting for race, sex, age, early HIV-related medical encounter, urban residence and TennCare enrollment category, black race, female sex and younger age were independent predictors of discontinuation among those starting PIs. Among persons starting NNRTIs, black race, younger age and a disability-based enrollment category predicted early drug discontinuation, but female sex did not.
CONCLUSIONS: Our results suggest that sociodemographic factors were associated with early NNRTI and PI discontinuation in this population, and some factors were ART class specific.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19110909      PMCID: PMC3816354          DOI: 10.1016/s0027-9684(15)31541-8

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  40 in total

1.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Authors:  David W Haas; Heather J Ribaudo; Richard B Kim; Camlin Tierney; Grant R Wilkinson; Roy M Gulick; David B Clifford; Todd Hulgan; Catia Marzolini; Edward P Acosta
Journal:  AIDS       Date:  2004-12-03       Impact factor: 4.177

Review 2.  Use of automated databases for pharmacoepidemiology research.

Authors:  B L Strom; J L Carson
Journal:  Epidemiol Rev       Date:  1990       Impact factor: 6.222

3.  Medicaid records as a valid data source: the Tennessee experience.

Authors:  C F Federspiel; W A Ray; W Schaffner
Journal:  Med Care       Date:  1976-02       Impact factor: 2.983

4.  Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study.

Authors:  Xiuhong Li; Joseph B Margolick; Craig S Conover; Sheila Badri; Sharon A Riddler; Mallory D Witt; Lisa P Jacobson
Journal:  J Acquir Immune Defic Syndr       Date:  2005-03-01       Impact factor: 3.731

5.  Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons.

Authors:  Todd Hulgan; Timothy R Sterling; Jim Daugherty; Patrick G Arbogast; Stephen Raffanti; Wayne Ray
Journal:  J Acquir Immune Defic Syndr       Date:  2005-03-01       Impact factor: 3.731

6.  Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.

Authors:  Esteban Ribera; Rosa M Lopez; Marjorie Diaz; Leonor Pou; Lidia Ruiz; Vicenç Falcó; Manuel Crespo; Carlos Azuaje; Isabel Ruiz; Imma Ocaña; Bonaventura Clotet; Albert Pahissa
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

7.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

8.  Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons.

Authors:  M R Griffin; W A Ray; W Schaffner
Journal:  Ann Intern Med       Date:  1988-09-01       Impact factor: 25.391

9.  Oral erythromycin and the risk of sudden death from cardiac causes.

Authors:  Wayne A Ray; Katherine T Murray; Sarah Meredith; Sukumar Suguna Narasimhulu; Kathi Hall; C Michael Stein
Journal:  N Engl J Med       Date:  2004-09-09       Impact factor: 91.245

10.  Recall accuracy for prescription medications: self-report compared with database information.

Authors:  S L West; D A Savitz; G Koch; B L Strom; H A Guess; A Hartzema
Journal:  Am J Epidemiol       Date:  1995-11-15       Impact factor: 4.897

View more
  5 in total

1.  Underutilization of the AIDS Drug Assistance Program: associated factors and policy implications.

Authors:  Noah C Godwin; James H Willig; Christa R Nevin; Hui-Yi Lin; Jeroan Allison; Kathy Gaddis; Jennifer Peterson; Michael S Saag; Michael J Mugavero; James L Raper
Journal:  Health Serv Res       Date:  2011-01-06       Impact factor: 3.402

2.  Sources of racial/ethnic differences in awareness of HIV vaccine trials.

Authors:  Michael P Arnold; Michele Andrasik; Stewart Landers; Shelly Karuna; Matthew J Mimiaga; Steven Wakefield; Kenneth Mayer; Susan Buchbinder; Beryl A Koblin
Journal:  Am J Public Health       Date:  2014-06-12       Impact factor: 9.308

3.  Cultural rationales guiding medication adherence among African American with HIV/AIDS.

Authors:  Andrea Sankar; Stewart Neufeld; Rico Berry; Mark Luborsky
Journal:  AIDS Patient Care STDS       Date:  2011-07-21       Impact factor: 5.078

4.  Nevirapine and tuberculosis predict first-line treatment failure in HIV patients in Indonesia: Case-control study.

Authors:  Yanri Wijayanti Subronto; Nur Aini Kusmayanti; Albarisa Shobry Abdalla; Prenaly Dwisthi Sattwika
Journal:  Ann Med Surg (Lond)       Date:  2020-10-15

5.  Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment.

Authors:  Dionne M Hines; Yao Ding; Rolin L Wade; Anne Beaubrun; Joshua P Cohen
Journal:  Patient Prefer Adherence       Date:  2019-11-07       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.